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ABSTRACT
Comparison of the Efficacy of Heparinized and
Non-heparinized Normal Saline Solutions
in Maintaining Patency of Arterial Catheters
By
Juanita K. Bogart

Although the need for heparin in flush solutions has not
been established, the currently accepted standard of
practice is to use heparinized solutions in arterial
catheter flush devices.

Exposure to heparin may place

patients at risk for developing heparin-induced
thrombocytopenia (HITP) and subsequent embolic events.
The purpose of the study was to test the null hypothesis
that there is no significant difference in patency of
arterial catheters maintained with heparinized or
non-heparinized normal saline solutions.

An experimental

design using a convenience sample (N=31) and random
assignment into experimental and control groups was used.
There was no statistically significant difference in
catheter patency between the two groups.
hypothesis was supported.
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CHAPTER ONE
INTRODUCTION

Invasive arterial cannulation for the purpose of
monitoring arterial waveform and providing access for
frequent blood sampling has become a routine part of
modern intensive care.

The patency of arterial catheters

is generally maintained with a continuous flow of a
solution containing heparin.

A recent survey conducted by

the American Association of Critical Care Nurses (AACN)
reported that 96% of 1,072 randomly selected critical care
nurses indicated that their institutions routinely
heparinized arterial catheter flush solutions (AACN,
1990).

Among the 96% who used heparinized solutions,

varying amounts of heparin were used in the flush
solution.
There are currently no standard guidelines for the
maintenance of arterial catheters in critically ill
patients.

While heparinized flush solutions have been

used to maintain the patency of arterial catheters since
their inception (Johnson & Ito, 1969), concern about the
risk of heparin-induced thrombocytopenia (HITP) has
prompted discussion of heparin-free alternatives (Baldwin,
1989; Warkentin & Kelton, 1989; Becker & Miller, 1989).
The reason for the efficacy of the flush solution is
unclear.

It may be caused by the anticoagulant or by the

continuous flow of fluid.

Recent studies have evaluated

the use of heparinized and non-heparinized solutions in
peripheral access devices and have suggested that
non-heparinized solutions may be as effective as
heparinized solutions in maintaining arterial line patency
(Epperson, 1984; Garrelts, LaRocca, Ast, Smith, & Sweet,
1989; Ashton, Gibson, & Summers, 1990).

There are to

date, however, very few studies evaluating the
contribution of heparin to line patency of arterial
pressure monitoring systems, and the reported results are
conflicting (Clifton, Branson, Kelly, Dotson, Record,
Phillips, & Thompson, 1991; Hook, Reuling, Luettgen,
Norris, Elsesser, & Leonard, 1987).
It is important that an effective and safe flush
solution be identified.

Nurses are in a key position to

evaluate effectiveness of flush solutions since they are
at the bedside and monitor the arterial waveform 24 hours
a day.
Problem Statement
The currently accepted standard of practice is to use
heparinized solutions in arterial catheter flush devices.
The need for heparin in flush solutions has not been
established.

The use of heparinized solutions in

peripheral access devices may not be necessary and may
unduly place patients at risk for developing HITP and
subsequent embolic events.

Therefore, it is necessary to

determine if non-heparinized solutions would maintain
patency of arterial catheters with as much efficacy as
heparinized solutions.
Purpose
The purpose of this study was to determine if there
was a significant difference in patency between arterial
catheters maintained with heparinized normal saline flush
solutions and those maintained with non-heparinized normal
saline flush solutions.

Patency was measured by

acceptable square waveform test and free backflow of
blood.

Measurements were done every four hours for

seventy-two hours after insertion of the catheter, or
until the catheter and line were removed, whichever came
first.
The research was one site of a multiple site study
being conducted by the American Association of Critical
Care Nurses called Thunder Project (Ledbetter, Ahrens,
Brown, Gawlinski, Quinn, & Walsh, 1991).

The data used

for this study was collected from a 300 bed acute care
hospital in the Midwest.

The author was the AACN site

coordinator for the hospital where data were collected
(see Appendix A).

CHAPTER TWO
LITERATURE AND CONCEPTUAL FRAMEWORK

Literature Review
Current and Past Nursing Practice.

Arterial

cannulation, the placement of an intra-arterial
catheter, is indicated for continuous arterial pressure
monitoring and to avoid the discomfort and injury from
frequent arterial punctures.

Arterial pressure is

monitored by periodic assessment of the arterial waveform.
The arterial waveform is a monitor tracing with visible
fluctuations caused by stretching and increased tension
within the arterial wall after each left ventricular
ejection (Vitello-Cicciu, 1988).

Patency of the arterial

catheter is determined by a square wave test.

This test

is performed by activating a fast flush device on the
arterial catheter solution tubing and assessing the
resulting change in arterial waveform (Ledbetter et al.,
1991).

Since 1959 heparinized flush solutions have been

recommended to maintain arterial catheters (Johnson & Ito,
1969; Gardner, Warner, Toronto, & Gaisford, 1970; Kaye,
1983; Hudson-Civetta & Caruthers-Banner, 1983).
Johnson and Ito (1969) described a new pressurized
tubing and flush system developed for monitoring arterial
waveform and maintaining arterial catheter patency.
recommended the use of heparinized solution in a

They

continuous low volume flush system.

They did not,

however, specify the concentration of heparin needed or
the preferred base solution.
Gardner et al. (1970) also described a similar
continuous flow system for arterial catheter and line
maintenance.
system.

They introduced the fast flush into the flow

This produced the square-wave test, an indication

of patency of the arterial catheter.

They recommended the

use of heparin in the flush solution, but did not indicate
the optimal concentration.
Opinions vary regarding the amount of heparin to be
added to the flush solution.

Kaye (1983) indicated that

2-4 units/ml. solution should be used.

Hudson-Civetta and

Caruthers-Banner (1983) recommended 10 units/ml.
A survey of randomly selected critical care nurses
was conducted by AACN (AACN, 1990).

Of the 1,072 who

responded, 96% indicated that heparinized flush solutions
were used for arterial lines in their institution.

There

was much variation in the concentration of heparin in the
flush solutions used by the institutions.

Thirty three

and one-half percent of respondents (n = 349) indicated
that their institutions used a 1:1 concentration of
heparin in arterial lines, 51.4% (n = 551) used a 2:1
concentration, only 9% (n = 97) used heparin
concentrations stronger than 2:1, and 2% (n = 20) used
non-heparinized solutions.

Clinical nurse specialists

from one critical care unit indicated that they had not
used heparinized solutions to maintain arterial catheter
patency for over five years and had no complications that
could be linked to the use of non-heparinized solution
(Jiricka, M., & Schweiger, J., personal communication,
December 14, 1990).

This seems to support continuous flow

rather than an anticoagulant for maintaining patency of
arterial catheters.
Pregnancy and Use of Heparin.

There are conflicting

reports in the literature about the safety of using
heparin during pregnancy.

Andrew et al. (1985) injected

radioactive heparin into sheep at 108-119 days gestation
(term: 147 days).

After 4 hours, blood samples were drawn

from each mother and fetus for measurements of activated
partial thromboplastin times and radioactivity.

There was

no detectable radioactivity or anticoagulant effect in any
fetus.

They concluded that heparin did not cross the

placental barrier.
Ginsberg, Hirsh, Turner, Levine, and Burrows (1989)
reviewed the literature and also reported that heparin was
not found to cross the placental barrier.

However, they

reported that the use of heparin during pregnancy is
problematic because of the potential adverse effects to
the mother.

These conflicting reports supported the

decision to use pregnancy as an exclusion criteria for
recruiting subjects in tbe present study since the fetus

could potentially be placed, at risk.
Heparin Induced Thrombocytopenia.

According to Irvin

(1990)/ heparin therapy is not without risk.

The

incidence of HITP may be much greater than reported.
HITP, a phenomenon in which heparin paradoxically causes
platelet aggregation, may be the most serious adverse
reaction associated with heparin use.
thrombi are usually arterial.

The resulting

If an embolic event occurs,

the results may be a stroke, myocardial infarction,
pulmonary embolus, loss of a limb, or death.
Chang (1987), in a retrospective study, reviewed the
charts of 23 clients who had received low-dose heparin
therapy and were suspected to have developed HITP.

Death

occurred in 40% (n = 9) and 13% (n = 3) needed amputation
of a limb.

Thrombocytopenia occurred 6-13 days after

initiation of the heparin therapy.
Becker and Miller (1989) described the incidence of
HITP in clients who had experienced strokes.

A literature

review identified 600 cases of stroke victims.

Over 50%

of the reported cases were a result of HITP and a
subsequent embolic event.

Prospectively, they estimated

that 10% of clients receiving heparin would develop HITP,
and of those, 10% would have a thrombo-embolic event,
resulting from even very small doses of heparin.

There

were no significant relationships between the amount of
heparin received and the incidence of HITP.

Severe cases

developed with doses as low as 240-500 units/day, an
amount commonly received in arterial catheter flush
solutions.

In contrast to Chang (1987),

who reported

that thrombocytopenia occurred 6-13 days after heparin
therapy was started, Becker and Miller (1989) reported
that an immune mediated response with catastrophic results
could occur within 30 minutes after a repeat exposure to
heparin.

Persistent sensitivity to heparin was found to

last up to 28 months after initial exposure.

The study

was limited by the selection of only clients who had
experienced strokes.
Warkentin and Kelton (1989) reviewed the literature
and estimated the incidence of HITP to be 5% of those
receiving heparin.

They reported adverse reactions to

include limb loss; myocardial infarction; pulmonary
embolism; thrombotic strokes; thrombosis of the
mesenteric, splenic, renal, and spinal arteries; adrenal
thrombosis; and hemorrhage.
Flush Solutions.

Most of the studies comparing the

effects of heparinized and non-heparinized solutions on
maintaining patency of catheters have been conducted in
populations requiring intravenous peripheral access
devices, more commonly called heparin locks.

Epperson

(1984) conducted a double-blind quasi-experiraental study
with a convenience sample (N = 412).

The hypothesis that

flush solutions containing 0.9% sodium chloride injection
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alone were as effective as 0.9% sodium chloride injection
containing either 10 or 100 units/ml. of heparin for
preventing loss of patency in heparin-lock sites was
supported.

There were no statistically significant

differences in length of patency of the device between the
groups.

A limitation of the study was the lack of random

assignment into experimental and control groups.

All

subjects admitted to the study unit for two months
received the first of the three flush solutions.

After

the initial two months a different solution was used for
two months on all subjects admitted to the unit.

The

procedure was repeated for the third solution.
Garrelts et al. (1989) conducted a prospective
randomized double-blind study on 147 subjects with a
heparin lock.

One group received heparin flushes, the

other received normal saline flushes.

Although there were

no significant differences in phlebitis or loss of
patency in the normal saline group, significantly more
non-occlusive fibrin clots (p=<.001) were found at the tip
of the catheter upon removal.

There were no new onset

stroke‘Or embolic events in any of the subjects.

Some

subjects from both groups refused to have the device
changed every 72 hours as the study protocol required.
The data were adjusted to a set length of 72 hours_for
these clients, even though the catheter was not removed
until much later.

The investigators in the study

speculated that the additional time beyond 72 hours may
have allowed more time for fibrin clots to form before the
catheter was inspected, thus affecting the results of the
study.
A study by Ashton et al. (1990) used a convenience
sample (N = 32) in a double-blind experimental design
comparing the use of normal saline with 10 units of
heparin/ml. and non-heparinized normal saline flush
in heparin lock devices.

The null hypothesis, that there

was no difference in the effectiveness of non-heparinized
and heparinized solutions in maintaining patency of
heparin lock devices, was supported.

The study was

limited by the small sample size and non-random sampling.
There were only two studies found that compared the
efficacy of heparinized and non-heparinized solutions in
arterial catheters.

Hook et al. (1987) used a convenience

sample (N = 50) with non-random assignment into groups for
a quasi-experimental study.

The subjects selected were

hospitalized for cardiovascular surgery.

The solutions

used in the study were plain lactated ringers in the
experimental group and lactated ringers with 2.5 units
heparin/ml in the control group.

There was no .

significant difference in patency variables, i.e. line
irrigated easily, line drew easily, cuff pressure equaled
monitor pressure +/- 10 mm Hg, and the line functioned
properly.

A good waveform was reported more frequently in
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the heparinized group than in the non-heparinized group
(p=.03).

There were three incidents of clot formation in

the non-heparin group and none in the heparin group,
however the difference in clot formation was not
significant (p=.13).

Most of the catheters had radial

artery placement (n = 48) and were in place less than 72
hours.

The study was limited by the use of a convenience

sample and non-random assignment into groups.
Clifton et al. (1991) used a double-blind
experimental design with a small convenience sample
(N = 30).

The research question was: Does heparin prolong

the functional lifespan of peripheral arterial catheters
and is there a difference in systemic adverse effects?
The study design was for 40 subjects.

Patency results

were tested for significant differences after data
collection was complete on 10, 20, and 30 subjects
respectively.

The study was stopped with 30 subjects

because of significant differences found in arterial
catheter patency (p=<.01).

The arterial catheters flushed

with 0.9% sodium chloride solution had a significantly
greater loss of oatencv rate than catheters flushed with a
4 units/ml heparin solution.

The study was limited by

all subjects having only,20 gauge radial catheters.

The

authors stated that they used only subjects with normal
platelet counts and coagulation indices, yet they used a
platelet count of less than 50,000/micrbTiter as inclusion
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criteria.

A level of less than 100,000/microliter is

considered by many to be thrombocytopenic (Irvin, 1990;
Chang, 1987; Warkenton & Kelton, 1989).
All arterial catheters place clients at risk
for clot formation and subsequent thrombo-embolic events
(Ledbetter et al., 1991).

Although some studies reported

fibrin clots in the catheters of subjects receiving
non-heparinized flush solution, there were no reports of
thrombo-embolic events (Hook et al., 1987; Garrelts et
al., 1989). The literature does not support an increased
risk associated with the use of non-heparinized flush
solutions (Ashton et al., 1990; Hook et al., 1987;
Epperson, 1984; Garrelts et al., 1989).
Conceptual Framework
Client/Client System.

Neuman (1989) conceptualized

the client/client system with concentric rings called
flexible and normal lines of defense and lines of
resistance which encircle a basic core (see Figure 1).
The client system includes five variables: physiological,
referring to bodily structure and function; psychological,
referring to mental processes and relationships;
sociocultural, referring to combined social and cultural
functions; developmental, referring to life developmental
processes; and spiritual, referring to spiritual belief
influence.

In this study the client is defined as anyone

who requires tbe placement of an arterial catheter for
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Figure 1

Intact Vascular
System with
Adequate Peripheral
and Central
"
Circulation/^ ^

Flexible Line of Defense

Normal Platelet
Aggregation

Normal Line of Defense
Normal
Coagulation
Lines of Resistance '

Basic
Core

Vital
\
Organ/Organ System
and Extremities.

Neuman's Conceptual Model Applied to Heparinized Flush Solutions.

(Adapted _from.Neuman, B., . a n d . Y o u n g , 1972. ...A jnodel for teaching
total person approach to patient problems. Nursing Research, 21, 265.)
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arterial waveform analysis or frequent blood sampling and
is admitted to either one of the two Intensive Care Units
(ICUs) of a hospital in the Midwest.
The basic core is composed of basic survival factors
common to the species such as normal temperature range,
genetic structure, response pattern, strength of organs
and organ systems, and ego structure.

These survival

factors are necessary to maintain system integrity and
life.

For the purpose of this study the basic core is

defined as any organ/organ system which sustains the life
of the client.

It also includes extremities which could

require amputation secondary to a thromboembolic event.
The lines of resistance are a series of broken
circles surrounding the basic core.

They are activated

following invasion by stressors of the normal line of
defense.

They contain certain factors which support the

individual's basic core, thus protecting system integrity.
Ineffectiveness of the lines of resistance in preventing
or reversing the reaction to stressors leads to energy
depletion and probable death.

The line of resistance of

interest to this study is an intact vascular system with
adequate peripheral and central blood flow to extremities
and organs/organ systems.
The normal line of defense is defined as the usual
wellness state of the client.
the client "has evolved.

This is a state to which

It is changed and adapted to over
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time.

When the normal line of defense is penetrated by a

stressor, symptomatology may begin to appear (Neuman,
1989, p. 29).

Normal coagulation is considered to be the

normal line of defense in this study.

Normal coagulation

includes a platelet count of greater than
100,000/microliter with the rest of the coagulation
process intact (Ledbetter et al., 1991).
The outermost ring, the flexible line of defense, is
a buffer to protect the normal line of defense from insult
by stressors.

It is dynamic rather than stable and can be

altered over a very short period of time, such as in
emergent situations.

Stressor impact, whether multiple or

single, has the potential for reducing the effectiveness
of the flexible line of defense.

In this study the

flexible line of defense is defined as normal platelet
aggregation.
Environment.

"The environment is broadly defined as

all internal and external factors or influences
surrounding the identified client or client system"
(Neuman, 1989, p. 31).

Stressors arise from the

environment and can be internal (intrapersonal) in nature,
external (interpersonal or extrapersonal) in nature, or a
created environment (intra-, inter-, or extrapersonal) in
nature.

A stressor is anything which produces disharmony

among the variables.
simultaneously.

More than one stressor may occur

Stressors may vary in impact and reaction
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produced.

Heparin, arising from a created extrapersonal

environment, is the stressor in this study.
Health. Wellness, or health, is defined as the
condition in which all five variables are in harmony with
the whole of the client.

Health for the client is viewed

"as being on a continuum and dichotomous with illness"
(Neuman, 1989, p. 33).

Disharmony among the variables

reduces the wellness state and is considered illness.
HITP is an illness state that can result from insult by
heparin to the normal line of defense, the coagulation
process.

In clients who are sensitive to it, heparin can

alter the cell wall of platelets causing them to aggregate
abnormally.

This decreases the number of platelets for

normal coagulation resulting in HITP.

The aggregated

platelets can lead to thrombus formation and subsequent
embolic events (Irvin, 1990).
Nursing.
prevention.

Neuman's model has three levels of

The first is primary prevention, such as

reducing the possibility of encounter with stressors and
strengthening the flexible line of defense.

Secondary

prevention consists of early case-finding and the
treatment of symptoms.

Tertiary prevention is the

maintenance of stability, rehabilitation, and reeducation
to prevent future occurrences.
The goal of nursing is to assist the individual to
attain/maintain an optimal wellness level.
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Any means by

which stressors can be reduced will decrease insults to
the basic core and the potential for death.

Eliminating

exposure to the stressor heparin in arterial catheter
flushes is a means of primary prevention.

This is

accomplished by reducing encounters with a stressor which
has the potential for penetrating the flexible line of
defense via alteration of platelet aggregation (Irvin,
1990)

and disruption of the coagulation process, the

normal line of defense, which results in HITP and the
potential for a thromboembolic event.

A thromboembolic

event could lead to obstructions in the vasculature
system, one line of resistance, causing loss of
extremities or death of the client, which results from
overwhelming insult to the basic core.

Determining the

efficacy of non-heparinized flush solution in arterial
catheters will result in knowledge which when applied,
will result in reducing insult to all lines of defense and
resistance and to the basic core of clients.
Hypothesis
The following null hypothesis was tested: There
will be no significant difference in patency of arterial
catheters maintained with heparinized or non-heparinized
normal saline solutions.
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CHAPTER THREE
METHODOLOGY

Design
The study, which was conducted at one site of a
multi-site study by AACN, used an experimental design and
compared subjects randomly assigned into two groups, those
with heparinized arterial flush solution as the control
group, and those with non-heparinized arterial flush
solution as the experimental group.

The heparinized flush

solution was the standard solution used by the hospital
and consisted of 2,000 units of heparin in one liter of
0.9% sodium chloride (normal saline) solution.

The

non-heparinized solution was normal saline.
Written approval for human subjects use was obtained
from human research review committee of Grand Valley State
University (see Appendix B ) .

Verbal approval to conduct

the study was obtained from an institutional review panel
in the hospital where data were collected.
Sample
A-convenience sample (N=31) was recruited from two
ICUs of a hospital in the Midwest.

Fifteen subjects were

in the control (heparin) group and sixteen were in the
experimental (no heparin) group.

Age ranged from 34-84

years with a mean of 68.94 years and a standard deviation
of 10.81 years.

Characteristics of the sample are listed
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in Table 1.

Both units were similar in size and patient

acuity and had a patient population that consisted of
medical, surgical, and neuro-trauma patients.
Inclusion and exclusion criteria were consistent with
those used by the AACN in Thunder Project (Ledbetter et
al., 1991).

Inclusion criteria consisted of the

following:
- measurement of arterial pressure and/or drawing blood
via arterial catheter required because of medical
condition
- 18 years of age or older
- arterial catheter connected to monitoring equipment
which could display waveform and fast flush
- enrolled in the study and placed in the appropriate
randomly assigned group at the time the arterial
catheter was inserted.
Exclusion criteria consisted of:
- known platelet count of less than 100,000/microliter
at the time of insertion of the arterial catheter
- enrolled in the study at a previous time
- enrolled in an experimental drug protocol
- known sensitivity to heparin or a physician's
order excluding heparin from the treatment plan
- pregnancy.
The use of drugs with anticoagulant effects were made note
of on the data collection instrument, but were not cause
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Table 1
Characteristics of the Sample fN=311
n

%

Gender
Male
Female

16
15

51.61
48.39

Ethnicity
Caucasian
Afro-American

28
3

90.32
9.68

Diagnosis
Medical
Surgical

23
8

74.19
25.81
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for exclusion from the study.

This was consistent with

the AACN study (Ledbetter et al., 1991).
Operational Definitions
Patency was defined as the maintenance of an
unobstructed arterial catheter as measured by two
criteria, acceptable square wave test and free backflow of
blood from the catheter.
Acceptable square wave test was achieved when upon
activation of the fast flush device, there was a rapid
upstroke which terminated in a flat line at the maximal
indicator on the tracing paper and, upon release of the
fast flush device, there was a rapid and unimpeded
downstroke approximating a 90 degree angle with a negative
deflection below baseline and a return to the arterial
waveform within 12/lOOths of a second (see Appendix C).
Free backflow of blood was defined as a flashback of
blood in the tubing at the interface of the catheter and
pressure tubing within one second when the stopcock was
turned off to the transducer and opened to air.
Heparinized flush solution was 0.9% sodium chloride
intravenous fluid containing the drug heparin in a 2:1
concentration.

The solution was infused continuously

under 300 mm Hg. pressure.
Non-heparinized flush solution was 0.9% sodium
chloride intravenous fluid without the addition of the
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drug heparin.

This solution was also infused continuously

under 300 mm Hg. pressure.
Instrument
Data collection instruments (see Appendix D) were
provided by AACN.

The instruments included tracings of

acceptable and dampened (non-acceptable) square waves to
assist the raters in accurate identification.

Also

included on the instrument were checklists for arterial
bag pressure, acceptable square wave, arterial backflow,
and use of anticoagulants since the previous data
collection time.

Demographic and clinical data were

collected on gender, age, ethnicity, primary diagnosis,
pressure monitoring system used, type of unit subject was
in at the time of the study, descriptives of the arterial
catheter used, type of arterial flush solution used, and
the use of any other arterial or central lines during the
study.
Content validity for the instrument was established
by a panel of experts from AACN with consideration of
clinical practice and the literature (Ledbetter et al.,
1991). - The clinical indicators of arterial line patency
that were used were suggested through research conducted
by Clifton et al. (1991), Hook et al. (1987), and Kaye
(1983).
Interratsr reliability for assessing patency and
treatment of arterial lines in the two groups was
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established and the protocol refined during Phase I and
Phase II of a pilot study by AACN (Ledbetter et al.,
1991).

During Phase I, preliminary instruments and

protocols were tested at one site with 11 subjects.

The

data collection instrument was revised based on input from
the site.

The level of interrater reliability for the

instruments, as established by AACN in the pilot studies,
was not specified.
Two sites and 34 subjects were used for Phase II of
the AACN pilot study.

The purpose of this phase was to

enlarge the number of subjects to identify data collection
problems, continue evaluation of safety, and to test the
revised instrument.

During this phase it was identified

that heparin and non-heparin lines were sometimes treated
differently.

The protocol was clarified and changes were

made in the inservice material presented to the data
collectors.
Phase III of the AACN pilot study consisted of 3
additional sites and 21 subjects.

The purpose of this

phase was to validate the instrument and the inservice
process and to continue monitoring the safety of the
protocol.

No changes were made in the instrument,

inservice process, or protocol during this phase.
Procedure
Staff registered nurses were inserviced by the
investigator.

"The inservice consisted of viewing a video
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tape prepared by AACN that described the data collection
protocol and data collection forms.

The staff nurses were

each given written guidelines for data collection (see
Appendix E ).

The procedure for obtaining informed consent

was presented by the investigator.

The staff nurses were

given a square wave form self assessment (see Appendix F)
to complete and return anonymously to the investigator.
Fifty percent of the self assessments were completed and
returned.

Interrater reliability for waveform

identification was established at .94, based on the self
assessment.

This may have been spuriously high because of

the low return rate on the self assessments.
A master log with random assignment into groups was
provided by AACN.

As subjects were recruited into the

study, the subject's hospital identification number was
placed on the next available space on the master log. This
made assignment into experimental or control group.
Subjects were recruited at the time consent for
arterial catheter insertion was obtained.

Informed

consent to participate in the study (see Appendix G) was
obtained from each subject, or the appropriate
representative if the subject was too ill to give consent.
Selection of the appropriate representative was determined
by the standard practice of

the hospital: a. spouse, b.

adult child, c. parent, d. adult sibling, e. guardian.
Data were collected b y unit staff registered
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nurses who had been inserviced on the data collection
protocol.

The time of the insertion of the catheter and

demographic and clinical data were placed on the data
collection instrument as soon as possible and less than
four hours after the insertion.

Four hour time intervals

were calculated and the appropriate data collection
points identified.

Data collection was performed at the

specified four hour intervals with an acceptable range of
plus or minus one hour.

Data collection continued for

seventy-two hours or until the catheter was removed,
whichever came first.

The data collected at the four hour

intervals were assessment of the arterial site, arterial
waveform, fast flushform, and whether or not the pressure
on the solution was at 300 mm Hg.
Risks were minimal.

In rare circumstances

thromboembolic events have occurred subsequent to the
placement of any invasive catheter.

There was no

increased risk to the client because of the study (Ashton
et al., 1990; Hook et al, 1987; Epperson, 1984; Garrelts
et al., 1989).
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CHAPTER FOUR
RESULTS

The results are reported according to demographic
characteristics and patency assessment.

Data were

analyzed with the use of the chi-square statistic and
student t-test to detect differences between groups and to
determine statistical significance.
level was set at p<.05.
for two by

The significance

The sample size was sufficient

two and two by three tables. A total of one

loss of patency in the

no heparin group

and noloss of

patency in

the heparin group resulted in emptycells and

cells with

an expected frequency of <5. Since

the low

loss of patency violated an assumption of sample size for
the chi-square statistic, a Yate's correction was used.
Sample Characteristics
The groups were equivalent in demographic and
arterial catheter characteristics.

Fifteen subjects were

in the control group and sixteen were in the experimental
group.

Arterial catheter characteristics are listed in

Table 2 .

Hours of data collection during catheter

placement ranged from 20 to 72 hours with a mean time of
59.74 hours (SD=I5.39).

Some catheters were removed for

reasons other than loss of patency before the 72 hour cut
off for data collection.

According to the AACN Thunder

Project protocol, data collection stopped at 72 hours even
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Table 2
Arterial Catheter Characteristics (N=31^

Site
Radial
Femoral
Brachial

-------------------21
67.74
8
25.81
2
6.45

Length
<2 cm.
>4 cm.

21
10

67.74
32.26

Gauge
22
20
18
16

2
19
7
3

6.45
61.29
22.58
9.68
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though some catheters remained in place longer.
Characteristics of the sample according to group
membership are shown in Table 3.

Arterial catheter

characteristics according to group membership are shown in
Table 4.

When the groups were compared for equivalence in

age the student t-test was used.

Mean age of the no

heparin group was 71.60 years (SD=5.33).

The mean age of

the heparin group was 66.44 years (SD=13.91).

The

difference in mean age between the groups was not
significant (T=1.38, df= 19.55, p=.18).

All other

variables were nominal level data for which the chi-square
test was used.

Although chi-square value varied among the

variables, there were no significant differences between
groups in gender, ethnicity, diagnosis, catheter site,
catheter length, or catheter gauge.
Patencv Assessment
The hypothesis that there would be no significant
difference in the patency of arterial catheters maintained
with heparinized or non-heparinized normal saline
solutions was supported.

As shown in Table 5, only one

subject lost patency of the arterial catheter.
subject was in the no heparin group.

This

The registered nurse

who determined that the catheter needed to be removed
reported that there was bruising at the catheter site.
She removed the catheter and documented it as loss of
patency.

The charge nurse in the unit at the time
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Table 3
Sample Characteristics According to Group Membership

Gender
Male
Female

No Heparin

Heparin

(n=16)

(n=15)

7
8

9
7

X^= .03
df=
1
p= .86

Ethnicity
Caucasian
Afro-American

14
1

14
2

X^= .00
df=
1
p=l.00

Diagnosis
Medical
Surgical

12
3

11
5

X^= .09
df=
1
p= .76
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Table 4
Arterial Catheter Characteristics
According to Group Membership
No Heparin

Heparin
(n=15)

(n=16)
Catheter Site
Radial
Femoral
Brachial

10
4
1

11
4

Catheter Length
<2cm.
>4cm.

10
5

11
5

Catheter Gauge
22
20
18
16

X2

X2= .02

df=
2
p= .99

1

X2= .00
df=
1
p=1.00

1

1

9
3
2

10
4
1

30

X^= .49
df=
3
p— .92

Table 5
Patencv Assessment

Patency*
Maintained
Loss of

*

No,Heparin

Heparin

Total

(n= 16)

(n= 15)

(N=31)

14
1

x2=.001, df=l, p=.97

31

16
0

30
1

reported that the bruising had been present prior to the
placement of the catheter.

A follow-up check of the

medical record indicated that there were no untoward
embolic events following the removal of the catheter.
The dependent variable in the hypothesis was patency.
The independent variable was type of flush solution.
variables were at the nominal level of measurement.

Both
The

chi-square statistic with Yate's correction was used to
determine if there was a statistically

significant

difference in catheter patency when heparinized and
non-heparinized normal saline flush solutions were used.
There was no significant difference in maintenance of
patency between the groups (X =.001, df=l, p=.97).

32

CHAPTER FIVE
DISCUSSION

Exposure to the stressor heparin has been associated
with life-threatening thromboembolic events (Irwin, 1990;
Chang, 1987; Warkenton & Kelton, 1989; Becker & Miller,
1989).

Historically, heparin has been used to maintain

arterial line patency despite the lack of empirical
evidence supporting the need for it.

Studies to provide

empirical evidence to support the efficacy of
hon-heparinized solutions in maintaining patency of
arterial catheters have had conflicting results.

Clifton

et al. (1991) found that arterial catheters flushed with
0.9% sodium chloride solution had a significantly greater
loss of patency than catheters flushed with heparinized
solution.

Hook et al. (1987) found no significant

differences in patency when arterial catheters were
flushed with heparinized and non-heparinized solutions.
Consistent with Hook et al. (1987), this study
demonstrated no significant difference in arterial
catheter patency between the catheters maintained with
heparinized solutions and those maintained with
non-heparinized solutions in equivalent groups.
The most frequent recipients of arterial catheters
are clients who have multiple insults to all lines of
resistance and to the basic core in many or all of the
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variables.

Much of the nursing care provided to these

clients is secondary or tertiary prevention as opposed to
primary prevention.

The Neuman Systems Model (Neuman,

1989) provides a useful conceptual framework for studying
primary prevention in these clients by eliminating the
stressor of heparin in maintaining patency of arterial
catheters.

The placement of the arterial catheter is a

created extrapersonal stressor which reduces the
effectiveness of the lines of resistance by disrupting the
vasculature system.

Heparin in the flush solution is an

additional stressor which may penetrate the flexible line
of defense by altering platelet aggregation.

Eliminating

the additional external stressor, heparin, is a means of
primary prevention.
This study built on the study of Hook et al. (1987).
Both studies found no significant difference in the
maintenance of patency of arterial catheters maintained
with heparinized and non-heparinized solutions.

This

suggests that patency can be maintained in arterial
catheters without stressing the client with heparin.

The

risk of HITP which results in insult to the basic core of
the client should be considered before routinely using
heparinized flush solutions to maintain catheter patency.
Limitations
The study was limited by the small sample size
(îi=3T).

A larger sample size would reduce the possibility
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that a Type' II error was made.

By using power analysis,

AACN determined that a sample size of N=11,000 was needed
(Ledbetter et al., 1991) for an alpha of .05 and power
equal to .80.
All of the subjects in this study had medical or
surgical diagnoses.

Trauma, burns, and neurological

insult are common diagnoses in critical care, but were not
represented in the sample of this study.

Because response

to stressors may vary with diagnosis, it cannot be assumed
that the results of this study would apply to any other
than a medical or surgical population.
This study used only 0.9% sodium chloride as the
flush solution for arterial catheters.

The 0.9% sodium

chloride solution was chosen because it was the customary
solution for the hospital in which data were collected.
According to the protocol for the AACN study (Ledbetter et
al., 1991) other solutions such as dextrose in water and
lactated ringers solution could be used in the flush
solution.

These other solutions, in the absence of the

heparin, may be as effective in maintaining patency of
arterial catheters as 0.9% sodium chloride, but this
cannot be assumed from the results of this study.
Nurses at the hospital where data were collected
reported that it was unusual to have 31 catheters and only
1 loss of patency.

Prior to the study it was common in

that hospital to lose patency in as many as T0% of

35

arterial catheters with the use of heparinized flush
solution.

The nurses speculated that the loss of patency

prior to the study may have been due in part to lack of
attentiveness in assessing and maintaining the catheters
by frequent flushing and waveform analysis.

During the

inservice for data collection the nurses were instructed
to treat all arterial catheters the same; to do nothing
different to the catheters in the heparin and non-heparin
groups (Appendix E, item 2).

All arterial catheters may

have been treated differently during this study than they
were prior to this study.

It is possible that they were

flushed more frequently, the pressure bags delivering 300
mm Hg pressure were checked and pressure maintained more
consistently, and the waveforms were analyzed on a more
regular basis.

If this did occur, there may be a

reasonable possible alternative hypothesis for the
findings of

this study.

decrease inthe loss of

It may be that there would be a
patency in arterial catheters when

the frequency of patency checks is increased.
Although the use of waveform and flush analysis and
backflow of blood in the pressure line are valid
measurements of arterial catheter patency (Kaye, 1983;
Johnson & Ito, 1969; Hudson-Civetta & Banner, 1983;
Gardener et

al., 1970),they may not have been measured

reliably in

this study.

A self assessment (Appendix F)
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was given to each nurse participating in data collection
and was to be returned anonymously to the author.

The

nurses may have collaborated in responding on the self
assessment, which may have altered the responses to the
measure used to determine interrater reliability of
waveform and flush analysis.

Because only 50% of the self

assessments were returned, the calculation of interrater
reliability may have been spuriously high.
Recommendations for Practice
Several studies reported in the literature suggest
that venous access devices can be maintained without
heparin (Ashton et al., 1990; Epperson, 1984; Garrelts et
al., 1989).

This study and Hook et al. (1987) suggest

that arterial catheters can be maintained with
non-heparinized normal saline solutions.
Recommendations for Future Research
Similar studies on multi-lumen central venous access
devices and pulmonary artery catheters would be beneficial
in evaluating the need for heparin in maintaining the
patency of these devices.

It may be possible that clients

could be spared the insult of the stressor heparin in all
types of invasive catheters.
Comparing different intervals of arterial catheter
patency checks could help answer the question that arose
from this study; why was there less loss of patency during
the study than prior to the study?
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More meticulous care

of arterial catheters and the flush system may
significantly decrease the incidence of loss of patency.
Solutions other than normal saline may not be as
effective in maintaining patency of arterial catheters in
the absence of heparin.

The AACN Thunder Project study

protocol did not limit the study sites to normal saline.
It was the only base solution used in this study because
it was the standard solution used by the hospital in flush
systems.

Future research using a variety of solutions is

needed.
Implications
The findings of this study and Hook et al. (1987),
provide implications for nursing practice.

The studies

suggest that a change of policies which specify the
routine use of heparin in flush solutions of arterial
catheters might be appropriate.

This would benefit

clients by reducing exposure to a created stressor,
heparin.

Comparing changes in platelet counts between

groups receiving heparinized and non-heparinized flush
solutions could provide valuable information on the effect
of low dose heparin in the development of
thrombocytopenia.

More studies are needed before any

policy changes should be made.

These studies should

include larger samples, examine the frequency of patency
checks, and use subjects with diverse medical diagnoses.
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D

£

Site Coordinator Acceptance

R

July 23,1991

Juanita Bogart, RN, ESN, CCRN
ICU Charge Nurse
Battle Creek Health System - Leila
300 North Avenue
Battle Creek, MI 49016
Dear Juanita:
Welcome to the educational and data collection phases of Thunder PmjecC*^. Your educational package
and 60 data collection packages will be arriving within 5 working days by UPS. You may want to alert your
institutional mail service to be eaqpecting this delivery. The boxes are prominentfy labeled, Thunder Project''**.
Endœ ed are the Thunder Project’''* pre-randomized Master Data Lists for your institution. As patients
enter the study, they are consecutively placed on the data list and receive their assignment to the heparin or non
heparin treatment groups based on their position on the list As discussed in your materials, you will need to
keep the lists in a central location for use by Site Research Assodates.
You have been assigned the institutional number of 094. This number needs to appear on all data
collection forms and on the institutional description form which will come with your educational materials.
If you do not receive your materials promptly or if you have questions when they arrive, call the
Research Department at the National Office for assistance. The office now has extended hours from 7:30 AM
to 5:30 PM Monday through Friday, West Coast time. Also, you may call and leave a message with the
answering service at any time.
Sincerely,

Karen R. Sechrist, PhD, RN, FAAN
Director of Research
Thunder Project"* Task Force
Staff Liaison

AACN
AMERICAN’ A S S O C IA T IO N
O F C R IT IC A L CAKE N U R S E S
PC) II,IS HODIIK
Lauuna NmucI, CA

714(144.9310
FAX 7 1 4 .6 4 0 4 9 0 3
TL.X 29(,937 AACN UK
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.GRAND
VALLEY
STATE
UNIVERSITY
1 CAMPUS DRIVE • ALLENDALE MICHIGAN 49401-9403 • 616/895^611

Approval by Human Subjects Review

December 12, 1991
Juanita Bogart
22109 Waubascon Rd.
Battle Creek, MI 49017

Dear Juanita:
The Human Research Review Committee of Grand Valley State University is
charged to examine proposals with respect to protection of human subjects. The
Committee has considered your proposal, ''Comparison of the Efficacy of
Heparinized and Non-heparinized Solutions in Maintaining Phtency of Arterial
Catheters", and is satisfied that you have complied with the intent of the
regulations published in the Federal Register 46 (16): 8386-8392, January 26,
1981.
Please note that approval is contingent upon the following modifications.
1.
2.

3.

When using the Informed Consent form with patients use a
shortened and easier version for them to understand.
In the Informed Consent document - change the last sentence
of the fourth paragraph to read - Risks are present whether
you choose to participate or not participate in this study.
In the Patient Acknowledgement section, the quotation marks
should be omitted and you should include a contact person
at the Battle Creek Health Center who the subject can contact
in the event of questions.

Sincerely,

Paul Huizenga, Chair
Human Research Review Comn '
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Acceptable Square Wave Test
Figure 2

Accaptabte Sauara Wav»

Dampened Scniaw Wava
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Data Collection Instruments
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Data Collection Instruments

AACN
CRTTICALCARE
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HEPARIN
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at the time the arterial Bneieineenad.
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4. Batiant hae a known sensitivity to heparin or eaisdng physioian order eaehidlng hspwkt from
die treatment plan.
B. Badent ia pregnant
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AACN THUNDER PROJECT
COMMENTS SHEET
T Hil/» 0 i »
"If the patient has received any of the following from sources
other than the arterial line in the study during the previous 4
hour of data collection, indicate yes in the thrombolytics/
anticoagulants data collection column:
Anticoagulants
Acelykalicylie acid (Aspirin)
Dipyridamole (Perandn)
Sulfinpyrazone (Anturane)
Heparin sodium (Hepaiean, Heparin Lock Flush Solution. Hep
Lock. Uquaemin Sodium)
Heparin calcium (Calcilean. Caldparine)
Warfarin sodium (Coumadin. Panwarfin, Wbrfilorw Sodum.
Carfin. Sofarin)
Dicumarol (Dicoumarin)
Anisindione (Miradon)
Thmmbolvties
Tissue plasminogen activator (t-PA) or Alteplasa (Activase)
APSAC or Anistreplase (Eminase)
Streptokinase (Kabikinase, Streptase)
\

COMMENTS
UNE
NUMBER
1
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AACN
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Patient has a known sensitivity to heparin or existing physician oniar excluding heparin from
th e treatm ent plan.
B. Patient is pregnant.__________________________________________________ ______________
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AACN THUNDER PROJECT
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Guidelines for Data Collection

AACN THUNDER PROJECT»^
SITE RESEARCH ASSOCIATE INFORMATION SHEET
Accuracy and consistency during data collection is of critical inçortance during the Thunder
Project"^. We would like to ask your cooperation in helping to maintain consistency and
accuracy during data collection in the following areas.
1.

Maintain your standard procedures for maintenance of arterial lines. Do not
change your technique, flushing or positioning procedures during the study.
It is important that your usual standard of care is maintained.

2.

Treat all arterial lines the same. Do nothing different to patients in the
heparin and non-heparin groups.

3.

Do not flush arterial lines with a syringe prior to performing the square wave
test

4.

Collect data in the order indicated on the data collection form, check arterial
pressure hzg, adjust pressure if indicated, perform square wave test check for
arterial backflow, determine if patient has received anticoagulants or
thrombolytics in the last four hours.

5.

Do not skip any data collection points. If a data collection point is missed by
up to 60 minutes, perform the data collection and fill in the data. If the data
collection is missed by greater than 60 minutes, omit the data collection point
and make a written comment on the appropriate line in the comments section.

6.

If the arterial flush solution is changed (lactated ringers to saline, for example)
indicate the change on the comments lines.

7.

At no time should the patient be changed from the heparin to non-heparin
group or vice versa. Should the physician order such a ^ange in the solution,
the data collection should be terminated and the patient removed from the
study.

8.

Indicate any unusual situations or changes on the comments section. Fill in
the circles where indicated. Please do not write on the data collection form
except in the comments section.

9.

If any untoward events occur while the patient is in the study, notify the site
"coordinator for instructions.

10.

Enjoy your participation in Thunder Projea^l
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Self Assessment

Darken the ^>propriate drde to indicate A ether the sançle square wave is acceptable or
dampened.
Exanq)le

Example
4.

Acceptable square wave

O yes

Q no

2.

Acceptable square wave

O yes

O no

Acceptable square wave O y e s

O no

5.

O yes

Q no

3.

Acceptable square wave

Acceptable square wave

6.

O
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Acceptable square wave

O yes
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Informed Consent
Comparison of the Efficacy of
Heparinized and Non-heparinized Solutions
in Maintaining Patency of Arterial Catheters
You are being asked to participate in a national multisite
research study developed by the American Association of Critical
Care Nurses. The study will evaluate the effects of heparinized
and non-heparinized flush solutions in maintaining an open and
functioning arterial catheter. The results of the study will help
determine which solution will best keep arterial catheters open
and working. During this study you will be placed into one of two
groups of patients. One group will have heparin in the flush
solution and the other will not. The decision to participate in
the study will not change the care you will receive and will not
involve any additional costs beyond those incurred during normal
care.
If clots form in the tubing, your doctor may have to remove the
arterial line. In very rare cases, a clot may cause a decrease or
loss of blood supply to the area beyond the catheter location.
Risks are present whether you choose to participate or not
participate in this study.
There are no immediate personal benefits to participation in the
study. Withdrawal from the study once data collection has begun
may or may not change the flush solution you receive.
Patient Acknowledaemmnt
I have been given an opportunity to ask questions regarding this
research study, and these questions have been answered to my
satisfaction. I understand that if I have any additional
questions I can contact Juanita Bogart, RN, at (615) 963-0436 or
(616) 966-8555.
In giving my consent, I understand that my participation in this
research project is voluntary, and that I may withdraw at any time
without affecting my future medical care.
I understand that this study is part of a national study by the
American Association of Critical Care Nurses and endorsed by the
Society of Critical Care Medicine. I also understand that the
investigator, Juanita Bogart, RN will use the information
collected on all of the study participants at Battle Creek Health
System to complete a thesis project for a Master of Science in
Nursing degree from Grand Valley State University. I hereby
authorize the investigator, Juanita Bogart, to release the
information obtained in this study to the American Association of
Critical Care Nurses for statistical analysis and to Grand Valley
State University. I understand that results will be reported as
group findings and not by individual names.
1 understand that neither Battle Creek Health System, Grand Valley
State University, nor Juanita Bogart agree to bear the expense of
medical care for any new illness or complications which may
develop during my participation in this study.
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Informed Consent

"I acknowledge that I have read and understand the above
information, and that I agree to participate in this study,
have received a copy of this document for my o%m records.*

Participant

Date

Witness

Date

__________ is unable to provide informed
The patient
consent due to his/her medical condition, consent is being
obtained from a family member/guardian.

Family Member/Guardian

Date

Relationship

Witness/Date
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